BioSpace News Archive

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced it has entered into a definitive agreement with a single institutional investor for the purchase and sale for $8,000,000 of (i) 1,200,000 Common Shares,

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today hosted a webcast and conference call highlighting its progress and key accomplishments in the first half of 2020.

10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2020 after market close on Tuesday, August 11, 2020.

The Public Health Agency of Canada is collaborating with provincial public health partners, the Canadian Food Inspection Agency and Health Canada to investigate an outbreak of Cyclospora infections occurring in three provinces.

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the “Company”), today announced the commencement of an underwritten public offering.

HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), today announced the pricing of the previously announced underwritten public offering of shares of its common stock.

Limitless Venture Group, Inc. announces a stock consolidation plan to shore up liquidity, expedite its capital raising plan, meet existing financing obligations to our majority acquisition Rokin, close its second majority acquisition, KetoSports, and launch HempLink, its on-line hemp trading app.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced that the first patient has been successfully dosed in a Phase 1b clinical trial (CIBI391A101) of TYVYT®

Revolution Medicines, Inc. announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $26.00 per share, before underwriting discounts and commissions.